睿智医药(300149) - 2024 Q1 - 季度财报(更新)

Revenue and Profit - The company's revenue for Q1 2024 was ¥234,594,741.64, a decrease of 12.68% compared to ¥268,658,644.91 in the same period last year[2] - The net profit attributable to shareholders was a loss of ¥25,460,550.66, slightly worsening from a loss of ¥25,145,108.24 year-over-year, reflecting a decrease of 1.25%[2] - Total operating revenue for Q1 2024 was CNY 234,594,741.64, a decrease of 12.7% compared to CNY 268,658,644.91 in Q1 2023[15] - The net profit for the first quarter was a loss of ¥25.50 million, compared to a loss of ¥25.17 million in the previous year, indicating a slight increase in losses[16] - The operating profit for the quarter was a loss of ¥27.27 million, an improvement from a loss of ¥28.41 million year-over-year[16] - The total comprehensive income for the quarter was a loss of ¥23.62 million, an improvement from a loss of ¥30.59 million in the same period last year[16] Cash Flow and Financial Activities - The net cash flow from operating activities improved significantly to ¥25,233,688.30, a 222.17% increase from a negative cash flow of ¥20,654,400.58 in the previous year[6] - The cash flow from operating activities was positive at ¥25.23 million, a significant turnaround from a negative cash flow of ¥20.65 million in the previous year[18] - The company reported a net cash outflow from investing activities of ¥32.71 million, compared to a positive cash inflow of ¥215.82 million in the same period last year[18] - The company experienced a foreign exchange impact on cash and cash equivalents amounting to ¥3.07 million, compared to a negative impact of ¥11.07 million in the previous year[19] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,346,414,163.14, down 3.61% from ¥2,434,322,930.12 at the end of the previous year[2] - The total current assets decreased from CNY 727,179,070.94 at the beginning of the period to CNY 676,526,244.27 at the end of the period, reflecting a decline of approximately 6.95%[12] - The company reported a total asset of CNY 2,346,414,163.14, a decrease from CNY 2,434,322,930.12 in the previous quarter[14] - Total liabilities amounted to CNY 909,152,366.32, down from CNY 973,437,322.12 in the previous quarter[14] - The company's equity attributable to shareholders was CNY 1,413,061,988.90, a decrease from CNY 1,436,646,599.86 in the previous quarter[14] Expenses - Total operating costs for Q1 2024 were CNY 263,463,408.41, down 13.3% from CNY 303,706,248.53 in the previous year[15] - Research and development expenses decreased to CNY 16,901,112.25, a reduction of 19.5% from CNY 20,950,769.76 in Q1 2023[15] - Management expenses decreased by 34.66% to ¥39,205,533.26, mainly due to reduced professional service fees[6] - Management expenses were CNY 39,205,533.26, down 34.6% compared to CNY 60,003,484.81 in the same period last year[15] - Financial expenses dropped significantly by 86.42% to ¥2,252,352.80, primarily due to foreign exchange gains from USD fluctuations[6] Shareholder Information - The top ten shareholders held a combined 56.12% of the company's shares, with the largest shareholder owning 13.69%[7] - The company's basic and diluted earnings per share both stood at -¥0.05, unchanged from the previous year[2] Other Financial Metrics - Other receivables increased by 44.56% to ¥17,362,357.45, primarily due to an increase in export tax refunds[6] - Contract assets rose by 73.12% to ¥7,365,099.02, attributed to receivables recognized based on project progress[6] - The company recorded a tax expense of approximately ¥1.94 million, a decrease from ¥3.11 million in the previous year[16] - The company reported a total of CNY 6,887,138.92 in prepayments, down from CNY 10,342,934.82, a decrease of approximately 33.5%[12] - The company’s other receivables increased from CNY 12,010,653.41 to CNY 17,362,357.45, an increase of about 44.5%[12] - The company’s contract assets increased from CNY 4,254,346.16 to CNY 7,365,099.02, reflecting an increase of approximately 73.5%[12] Future Outlook - The company is focusing on cost reduction strategies, as indicated by the significant decrease in operating costs and management expenses[15] - Future outlook includes continued emphasis on R&D and potential market expansion, although specific figures were not provided in the report[15]